St. David's South Austin Medical Center Enrolls First Patient Globally in Phase III CAR T-Cell Trial for Aggressive Large B-Cell Lymphoma
核心洞察
St. David's South Austin Medical Center (搜索) became the first site worldwide to enroll a patient in a phase III clinical trial evaluating rondecabtagene autoleucel (搜索) (ronde-cel (搜索)), a next-generation CAR T-cell therapy for aggressive large B-cell lymphoma (搜索).
The head-to-head trial will compare ronde-cel (搜索)'s safety and efficacy against approved CD19 (搜索) CAR T-cell therapies in approximately 400 patients with relapsed or resistant large B-cell lymphoma (搜索) receiving second-line treatment.
Ronde-cel (搜索) is designed to target both CD19 (搜索) and CD20 (搜索) proteins on cancerous B-cells, potentially improving detection of cancer cells that often evade single-target treatments.
St. David's South Austin Medical Center (搜索) has achieved a significant milestone in cancer research by becoming the first site globally to enroll a patient in a groundbreaking phase III clinical trial evaluating rondecabtagene autoleucel (搜索) (ronde-cel (搜索)), a next-generation CAR T-cell therapy for aggressive large B-cell lymphoma (搜索). The Sarah Cannon Transplant & Cellular Therapy Program (搜索) at the medical center enrolled the world's first participant in this first-of-its-kind head-to-head CAR T-cell clinical trial on April 20, 2026.
Novel Dual-Target CAR T-Cell Therapy
The investigational therapy ronde-cel (搜索) builds upon the established promise of CAR T-cell therapy, which reprograms a patient's own immune cells to better recognize and attack cancer. Unlike traditional treatments, CAR T-cell therapy offers a more personalized approach and has already transformed treatment paradigms for certain blood cancers.
What distinguishes ronde-cel (搜索) from existing therapies is its dual-targeting mechanism. "By targeting two specific proteins—CD19 (搜索) and CD20 (搜索)—ronde-cel is designed to better detect cancer cells that often evade treatment," explained Dr. Uttam Rao, principal investigator for the study at the Sarah Cannon Transplant & Cellular Therapy Program (搜索).
Phase III Trial Design and Objectives
The global clinical trial will evaluate the efficacy and safety of ronde-cel (搜索) versus the investigator's choice of approved CD19 (搜索) CAR T-cell therapies in patients with aggressive large B-cell lymphoma (搜索) receiving treatment in the second-line setting. The study targets patients with relapsed or resistant disease, representing a critical unmet medical need in oncology.
The trial's primary goal is to measure how long patients remain free from cancer progression or major complications. Approximately 400 participants will be enrolled globally across multiple sites, making this one of the largest comparative studies in the CAR T-cell therapy space.
"This study represents an important step forward in how we treat relapsed or resistant large B-cell lymphoma (搜索)," Dr. Rao stated. "Through our collaboration with SCRI, we are able to bring cutting-edge cancer research directly to patients in Central Texas."
Research Infrastructure and Global Leadership
St. David's South Austin Medical Center (搜索)'s achievement in securing the first global enrollment underscores the strength of its research infrastructure and commitment to providing patients with early access to advanced therapies. The medical center operates through the Sarah Cannon Research Institute (搜索) (SCRI) and leverages SCRI's Accelero model, which enabled rapid trial activation and successful patient enrollment.
"Being the first site globally to enroll a patient underscores the strength of our research infrastructure and our commitment to offering patients early access to the most advanced therapies available," Dr. Rao emphasized.
The medical center is part of the Sarah Cannon Transplant & Cellular Therapy Network, which represents the largest provider of blood and marrow transplants and cellular therapies in the United States. This collaboration brings early-phase clinical trials and advanced cell and gene therapies to patients in Central Texas, eliminating the need for patients to travel far from home for access to promising new treatments.
Clinical Significance and Future Impact
The enrollment milestone positions Austin at the forefront of next-generation cancer care and represents a significant advancement in personalized cancer treatment. By making this therapy available to patients before it becomes available anywhere else globally, the medical center demonstrates how global medical innovation can occur at the local level.
The trial has the potential to change the standard of treatment for aggressive blood cancers, particularly for patients whose disease has relapsed or proven resistant to initial therapy. The dual-targeting approach of ronde-cel (搜索) may address a key limitation of current single-target CAR T-cell therapies, potentially improving long-term outcomes for patients facing this challenging diagnosis.
As the study progresses with its planned enrollment of 400 participants worldwide, the results will provide crucial comparative data on the safety and effectiveness of this next-generation CAR T-cell therapy against currently approved treatments, potentially establishing a new standard of care for aggressive large B-cell lymphoma (搜索) in the second-line setting.